Is NL-GHK-CU suitable for both men and women
Lee YJ, Javdan B, Cowan A, Smith K
The FDA could act soon on the first two, and more new drugs are in the works Novo Nordisk's obesity pill made it through the FDA first
The trial in people with T2D included 281 participants (mean age 56 years, 56% women, mean BMI 35.0 kg/m 2 , mean HbA1c 8.3%) treated with lifestyle only and/or metformin, with similar intervention arms to the obesity trial, albeit retatrutide 0.5 mg rather than 1 mg, and dulaglutide 1.5 mg was an additional comparator [46]
The mechanistic comparison is particularly interesting: CagriSema adds amylin signaling to GLP-1, while retatrutide adds glucagon and GIP signaling
10.1002/bdd.2510110205 13 Brigelius-FlohR